Q-omics provides the consensus-scored OPN5 profile across patient tissues and cancer cell-line models. OPN5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, OPN5 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, OPN5 protein abundance shows 11,369 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where OPN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OPN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OPN5 survival associations across molecular data types. OPN5 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OPN5 RNA expression–survival associations across cancer types. High OPN5 expression shows unfavorable associations in UVM, COAD, ACC, SCLC, LUAD and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for OPN5 RNA expression.
This table summarizes OPN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for OPN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OPN5 shows higher tumor expression in THCA, KIRP and STAD. The THCA box plot shows higher OPN5 RNA expression in tumor versus normal tissue (log2 FC = +0.081, t-test p < 0.001).
This table shows molecular features associated with OPN5 in patient tissues and cancer cell lines. In patient samples, OPN5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OPN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
